> top > docs > PubMed:33582664 > annotations

PubMed:33582664 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-86 Sentence denotes Colchicine for Left Ventricular Infarct Size Reduction in Acute Myocardial Infarction:
T2 87-196 Sentence denotes A Phase II, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Protocol - The COVERT-MI Study.
T3 197-343 Sentence denotes Inflammatory processes have been identified as key mediators of ischemia-reperfusion injury in ST-segment elevation myocardial infarction (STEMI).
T4 344-496 Sentence denotes They add damage to the myocardium and are associated with clinical adverse events (heart failure and cardiovascular death) and poor myocardial recovery.
T5 497-574 Sentence denotes Colchicine is a well-known alkaloid with potent anti-inflammatory properties.
T6 575-842 Sentence denotes In a proof-of-concept phase II trial, colchicine has been associated with a significant 50% reduction of infarct size (assessed by creatine kinase levels) in comparison to placebo in acute STEMI patients referred for primary percutaneous coronary intervention (PPCI).
T7 843-1135 Sentence denotes The Colchicine in STEMI Patients Study (COVERT-MI) is an ongoing confirmative prospective, multicenter, randomized, double-blind trial testing whether a short course oral treatment with colchicine versus placebo decreases myocardial injury in patients presenting with STEMI referred for PPCI.
T8 1136-1388 Sentence denotes Adult patients, with a first STEMI episode and an initial TIMI flow ≤1, referred for PPCI, will be randomized (n = 194) in a 1:1 ratio to receive an oral bolus of colchicine of 2 mg followed by 0.5 mg b.i.d. treatment during 5 days or matching placebo.
T9 1389-1524 Sentence denotes The primary endpoint will be the reduction in infarct size as assessed by cardiac magnetic resonance at 5 ± 2 days between both groups.
T10 1525-1780 Sentence denotes The main secondary endpoints will be tested between groups in hierarchical order with left ventricular ejection fraction at 5 days, microvascular obstruction presence at 5 days, and absolute adverse left ventricular remodeling between 5 days and 3 months.
T11 1781-1881 Sentence denotes This academic study is being financed by a grant from the French Ministry of Health (PHRCN-16-0357).
T12 1882-2020 Sentence denotes Results from this study will contribute to a better understanding of the complex pathophysiology underlying myocardial injury after STEMI.
T13 2021-2097 Sentence denotes The present study describes the rationale, design, and methods of the trial.
T1 0-86 Sentence denotes Colchicine for Left Ventricular Infarct Size Reduction in Acute Myocardial Infarction:
T2 87-196 Sentence denotes A Phase II, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Protocol - The COVERT-MI Study.
T3 197-343 Sentence denotes Inflammatory processes have been identified as key mediators of ischemia-reperfusion injury in ST-segment elevation myocardial infarction (STEMI).
T4 344-496 Sentence denotes They add damage to the myocardium and are associated with clinical adverse events (heart failure and cardiovascular death) and poor myocardial recovery.
T5 497-574 Sentence denotes Colchicine is a well-known alkaloid with potent anti-inflammatory properties.
T6 575-842 Sentence denotes In a proof-of-concept phase II trial, colchicine has been associated with a significant 50% reduction of infarct size (assessed by creatine kinase levels) in comparison to placebo in acute STEMI patients referred for primary percutaneous coronary intervention (PPCI).
T7 843-1135 Sentence denotes The Colchicine in STEMI Patients Study (COVERT-MI) is an ongoing confirmative prospective, multicenter, randomized, double-blind trial testing whether a short course oral treatment with colchicine versus placebo decreases myocardial injury in patients presenting with STEMI referred for PPCI.
T8 1136-1388 Sentence denotes Adult patients, with a first STEMI episode and an initial TIMI flow ≤1, referred for PPCI, will be randomized (n = 194) in a 1:1 ratio to receive an oral bolus of colchicine of 2 mg followed by 0.5 mg b.i.d. treatment during 5 days or matching placebo.
T9 1389-1524 Sentence denotes The primary endpoint will be the reduction in infarct size as assessed by cardiac magnetic resonance at 5 ± 2 days between both groups.
T10 1525-1780 Sentence denotes The main secondary endpoints will be tested between groups in hierarchical order with left ventricular ejection fraction at 5 days, microvascular obstruction presence at 5 days, and absolute adverse left ventricular remodeling between 5 days and 3 months.
T11 1781-1881 Sentence denotes This academic study is being financed by a grant from the French Ministry of Health (PHRCN-16-0357).
T12 1882-2020 Sentence denotes Results from this study will contribute to a better understanding of the complex pathophysiology underlying myocardial injury after STEMI.
T13 2021-2097 Sentence denotes The present study describes the rationale, design, and methods of the trial.